Various studies (26, 28, 29) have identified specific SNPs within the PNPLA3 gene that are linked to the onset and advancement of NAFLD, suggesting PNPLA3 as a promising therapeutic target for further investigation into these conditions. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.